43 Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors

• Joseph Markowitz,
• Yana G Najjar,
• Michael P Brown,
• Dennie Frederick,
• Genevieve M Boland,
• Klaus Lindpaintner,
• Gege Xu,
• Rachel Rice,
• Daniel Serie,
• Lisa M Ebert,
• Alan Mitchell,
• Xin Cong,
• Gonzalo Tapia-Rico,
• Chad Pickering,
• Paul Aiyetan,
• Ranjan Bhadra,
• Chirag Dhar,
• Flavio Schwarz

Affiliations

Joseph Markowitz

Aff1 grid.468198.a0000000098915233Department of Cutaneous OncologyH. Lee Moffitt Cancer Center and Research Institute 12902 Magnolia Drive 33612-9416 Tampa FL USA

Yana G Najjar

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Michael P Brown

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Dennie Frederick

Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Genevieve M Boland

Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Klaus Lindpaintner

Strategic Diagnostics Inc. (SDI), Newark, New Jersey, USA

Gege Xu

1InterVenn, Concord, NH, USA

Rachel Rice

1InterVenn, Concord, NH, USA

Daniel Serie

1InterVenn, Concord, NH, USA

Lisa M Ebert

Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia

Alan Mitchell

InteVenn Bioscience, South San Francisco, CA, USA

Xin Cong

InteVenn Bioscience, South San Francisco, CA, USA

Gonzalo Tapia-Rico

2Icon Cancer Centre, Adelaide, Australia

Chad Pickering

2InterVenn Biosciences, South San Francisco, CA, USA

Paul Aiyetan

2InterVenn Biosciences, South San Francisco, CA, USA

Ranjan Bhadra

2InterVenn Biosciences, South San Francisco, CA, USA

Chirag Dhar

2InterVenn Biosciences, South San Francisco, CA, USA

Flavio Schwarz

2InterVenn Biosciences, South San Francisco, CA, USA